Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-07
Combretastatin A4
Cat. No.
AKA-07
CAS No.
117048-59-6
MF
C18H20O5
MW
316.353
Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Combretastatin A4
CAS No.
117048-59-6
MF
C18H20O5
MW
316.353
Specification
99%
Research Area
Intermediate
Description
Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: In stock
Documents
Can't find the right version? Our team of experienced experts is here for you with full support.Contact Us
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Tochinai R, et al. Combretastatin A4 disodium phosphate-induced myocardial injury. Journal of Toxicologic Pathology. 2016 Jul;29(3):163-71.
[2]. Signoretto E, et al. Stimulation of Eryptosis by Combretastatin A4 Phosphate Disodium (CA4P). Cellular Physiology and Biochemistry. 2016;38(3):969-981.
[3]. Zhu J, et al. Co-Encapsulation of Combretastatin-A4 Phosphate and Doxorubicin in Polymersomes for Synergistic Therapy of Nasopharyngeal Epidermal Carcinoma. Journal of Biomedical Nanotechnology. 2015 Jun;11(6):997-1006.
[4]. Yao N, et al. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo. Tumour Biology. 2015 Nov;36(11):8499-510.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
